Duxin Sun

56PUBLICATIONS
100CO-AUTHORS
Radiation therapySeparation technologiesBiologically active moleculesMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (56)

|Sep 24, 2026
Rac1 and CHK1 Converge on Abi-1 to Regulate DNA Repair Dependency and Treatment Response in Human Cancers.

|Jul 05, 2026
Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

|Jun 23, 2026
Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

|May 26, 2026
Machine Learning Model Predicts Clinical Adverse Events of Small Molecule Kinase Inhibitors in Cancer Patients Using On-/Off-Target Engagement and Tissue Selectivity.

|Apr 28, 2026
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.

|Mar 23, 2026
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader.

Dimin Wu, Haibin Zhou, Longchuan Bai

Pageof 10

Frequent Collaborators

25 joint publications

Shaomeng Wang

8 joint publications

Chao-Yie Yang

8 joint publications

Rohan Kalyan Rej

7 joint publications

Ranjan Kumar Acharyya